| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $13,698,433 | 25 | 100 |
| Henderson Jane | Chief Financial Officer | 0 | $0 | 7 | $1.14M | $-1.14M |
| Dambkowski Carl | Chief Medical Officer | 0 | $0 | 12 | $4.26M | $-4.26M |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | 0 | $0 | 6 | $8.3M | $-8.3M |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Over the last 12 months, insiders at Apogee Therapeutics, Inc. have bought $0 and sold $13.7M worth of Apogee Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Apogee Therapeutics, Inc. have bought $25.5M and sold $12.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $990,775 was made by McKenna Mark C. (director) on 2024‑12‑12.
| 2026-01-14 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0359% | $81.11 | $1.62M | +1.30% | |
| 2026-01-07 | Sale | Dambkowski Carl | Chief Medical Officer | 18,700 0.034% | $77.84 | $1.46M | +1.51% | |
| 2026-01-06 | Sale | Henderson Jane | Chief Financial Officer | 2,000 0.0038% | $80.00 | $160,000 | +1.62% | |
| 2026-01-02 | Sale | Henderson Jane | Chief Financial Officer | 6,000 0.0109% | $74.86 | $449,146 | +2.86% | |
| 2025-12-19 | Sale | Henderson Jane | Chief Financial Officer | 1,500 0.0028% | $80.00 | $120,000 | -1.57% | |
| 2025-12-10 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0368% | $75.38 | $1.51M | +1.60% | |
| 2025-12-04 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 40,000 0.0725% | $75.01 | $3M | +2.09% | |
| 2025-12-04 | Sale | Dambkowski Carl | Chief Medical Officer | 10,900 0.0197% | $75.00 | $817,500 | +2.09% | |
| 2025-12-04 | Sale | Henderson Jane | Chief Financial Officer | 1,500 0.0027% | $75.00 | $112,500 | +2.09% | |
| 2025-11-25 | Sale | Henderson Jane | Chief Financial Officer | 1,500 0.0029% | $70.00 | $105,000 | +7.91% | |
| 2025-11-14 | Sale | Henderson Jane | Chief Financial Officer | 2,000 0.0038% | $65.00 | $130,000 | +16.14% | |
| 2025-11-13 | Sale | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 20,000 0.0365% | $63.01 | $1.26M | +20.79% | |
| 2025-11-11 | Sale | Henderson Jane | Chief Financial Officer | 1,000 0.0019% | $60.00 | $60,000 | +20.38% | |
| 2025-11-05 | Sale | Dambkowski Carl | Chief Medical Officer | 10,785 0.0179% | $55.07 | $593,903 | +36.59% | |
| 2025-10-01 | Sale | Dambkowski Carl | Chief Medical Officer | 5,110 0.0087% | $39.80 | $203,378 | +70.28% | |
| 2025-09-03 | Sale | Dambkowski Carl | Chief Medical Officer | 2,725 0.0046% | $37.87 | $103,198 | +48.99% | |
| 2025-08-06 | Sale | Dambkowski Carl | Chief Medical Officer | 2,725 0.0045% | $37.78 | $102,951 | +51.84% | |
| 2025-07-02 | Sale | Dambkowski Carl | Chief Medical Officer | 10,090 0.0172% | $45.09 | $454,954 | +18.16% | |
| 2025-06-04 | Sale | Dambkowski Carl | Chief Medical Officer | 2,725 0.0046% | $36.96 | $100,716 | +18.32% | |
| 2025-05-07 | Sale | Dambkowski Carl | Chief Medical Officer | 2,725 0.0047% | $35.75 | $97,419 | +16.86% |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | 1192987 2.1757% | $96.36M | 0 | 12 | |
| Dambkowski Carl | Chief Medical Officer | 212523 0.3876% | $17.17M | 0 | 19 | |
| Henderson Jane | Chief Financial Officer | 185371 0.3381% | $14.97M | 0 | 8 | |
| Fairmount Funds Management LLC | director | 1992734 3.6341% | $160.95M | 1 | 0 | +50.02% |
| McKenna Mark C. | director | 20000 0.0365% | $1.62M | 1 | 0 | <0.0001% |
$159,914,414 | 243 | 18.52% | $3.65B | |
$66,736,176 | 136 | 27.54% | $3.8B | |
$193,151,375 | 134 | 8.18% | $4.43B | |
$52,263,649 | 70 | 1.18% | $4.12B | |
$104,428,685 | 44 | 22.55% | $3.3B | |
$224,382,625 | 44 | 27.62% | $4.71B | |
$477,065,869 | 34 | 82.05% | $5.29B | |
$1,275,975,557 | 32 | 19.44% | $4.4B | |
$74,605,681 | 14 | 47.06% | $5.1B | |
$2,477,801 | 11 | 4.98% | $5.22B | |
$3,073,199 | 10 | 16.77% | $4.95B | |
$35,908,794 | 10 | 126.31% | $5.13B | |
$25,064,843 | 9 | 12.75% | $4.59B | |
$1,711,150 | 9 | 31.59% | $3.83B | |
$2,246,813 | 6 | 70.15% | $4.85B | |
$182,500,000 | 6 | 29.00% | $3.99B | |
$461,215 | 5 | 10.35% | $3.59B | |
Apogee Therapeutics, Inc. (APGE) | $50,990,767 | 2 | 19.79% | $4.43B |
$7,600,000 | 1 | -4.05% | $4.41B |
| Increased Positions | 89 | +41.4% | 8M | +13.42% |
| Decreased Positions | 93 | -43.26% | 6M | -10.95% |
| New Positions | 27 | New | 2M | New |
| Sold Out Positions | 31 | Sold Out | 3M | Sold Out |
| Total Postitions | 211 | -1.86% | 60M | +2.46% |
| Vr Adviser, Llc | $643,624.00 | 15.44% | 8.49M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $524,129.00 | 12.58% | 6.92M | +9,362 | +0.14% | 2025-09-30 |
| Wellington Management Group Llp | $357,962.00 | 8.59% | 4.72M | +917,991 | +24.12% | 2025-09-30 |
| Rtw Investments, Lp | $205,523.00 | 4.93% | 2.71M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $203,547.00 | 4.88% | 2.69M | +123,487 | +4.82% | 2025-09-30 |
| Vanguard Group Inc | $170,174.00 | 4.08% | 2.25M | +136,693 | +6.48% | 2025-09-30 |
| Driehaus Capital Management Llc | $163,571.00 | 3.93% | 2.16M | -152,253 | -6.59% | 2025-09-30 |
| Fairmount Funds Management Llc | $155,246.00 | 3.73% | 2.05M | 0 | 0% | 2025-09-30 |
| State Street Corp | $125,457.00 | 3.01% | 1.66M | +396,290 | +31.47% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $115,319.00 | 2.77% | 1.52M | +563,127 | +58.74% | 2025-09-30 |